Stenotrophomonas maltophilia resistant to trimethoprim-sulfamethoxazole: an increasing problem.
Stenotrophomonas maltophilia (S. maltophilia) has recently emerged as an important nosocomial pathogen. Treatment of invasive infections caused by this organism is difficult as the bacterium is frequently resistant to a wide range of commonly used antimicrobials. Trimethoprim-sulfamethoxazole (TMP - SXT) is recommended as the agent of choice for the treatment of S. maltophilia infections. However, the development of resistance to this antibiotic represents a real challenge to laboratorians and clinicians. This letter describes the first isolation of S. maltophilia resistant to TMP - SXT from two patients treated at Riyadh Armed Forces Hospital which is a major tertiary hospital in Saudi Arabia.
Al-Jasser
Asma Marzouq
AM
Department of Microbiology, Armed Forces Hospital, Box X-966, P.O. Box 7897, Riyadh - 11159, Saudi Arabia. asjass2002@yahoo.com
D000368:Aged; D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use*; D003428:Cross Infection / Q000188:drug therapy*; D024881:Drug Resistance, Bacterial; D004359:Drug Therapy, Combination; D017809:Fatal Outcome; D005260:Female; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012529:Saudi Arabia; D012772:Shock, Septic / Q000209:etiology; D020615:Stenotrophomonas maltophilia / Q000187:drug effects*; D013420:Sulfamethoxazole / Q000494:pharmacology / Q000627:therapeutic use; D016896:Treatment Outcome; D014295:Trimethoprim / Q000494:pharmacology / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D014295:Trimethoprim; D013420:Sulfamethoxazole